Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

1. Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis

Azelastine hydrochloride and fluticasone propionate (Dymista nasal spray suspension) - moderate to severe seasonal and perennial allergic rhinitis HAS - Medical, Economic and Public Health Assessment Division 1/17 Opinion 2 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 DYMISTA 137 µg/50 µg, nasal spray suspension Bottle with 23 g suspension of 25 ml or around 120 doses (CIP: 34009 275 631 1 9 (...) ) Applicant: MEDA PHARMA INN Azelastine hydrochloride, fluticasone propionate. ATC Code (2013): R01AD58 (nasal corticosteroid, combinations) Reason for the request Inclusion Lists concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123-2) Indications concerned "Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient

2014 Haute Autorite de sante

2. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) Chronic obstructiv Chronic obstructive pulmonary disease: e pulmonary disease: fluticasone furoate, umeclidinium and vilanterol fluticasone furoate, umeclidinium and vilanterol (T (T relegy) relegy) Evidence summary Published: 14 June 2018 nice.org.uk/guidance/es18 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2018. See summaries of product (...) characteristics (SPC), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory status: Regulatory status: Fluticasone furoate/umeclidinium/vilanterol (Trelegy, GlaxoSmithKline UK) received a European marketing authorisation in November 2017. This triple-therapy inhaler contains an inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA). It is licensed for maintenance treatment of adults with moderate- to-severe

2018 National Institute for Health and Clinical Excellence - Advice

3. Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years

Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years 1 Published 10 June 2019 1 Product update SMC2178 fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) Napp Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland. Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting ß 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting ß 2 agonist. Or • For patients

2019 Scottish Medicines Consortium

4. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Full Text available with Trip Pro

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority (...) trial. Patients who had COPD with a history of at least one exacerbation during the previous year were randomly assigned to receive, by inhalation, either the LABA indacaterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. The primary outcome was the annual rate of all COPD exacerbations.A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol

2016 NEJM Controlled trial quality: predicted high

5. Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02502734 Recruitment Status : Completed First Posted : July 20, 2015 Results First Posted : July 29, 2016 Last Update Posted

2015 Clinical Trials

6. Fluticasone

Fluticasone Top results for fluticasone - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluticasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

7. Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2018 Clinical Trials

8. Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15

Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 1 Translation of addendum A18-46 Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 (Version 1.0; Status: 26 July 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 26 July 2018 1.0 Commission: A18-46 Version: Status: IQWiG Reports (...) – Commission No. A18-46 Fluticasone furoate/ umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 1 Addendum A18-46 Version 1.0 FF/UMEC/VI – Addendum to Commission A18-15 26 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Fluticasone furoate/umeclidinium/vilanterol (COPD) – Addendum to Commission A18-15 Commissioning agency: Federal Joint Committee Commission awarded on: 09 July

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Are there any adverse effects associated with fluticasone use?

Are there any adverse effects associated with fluticasone use? Are there any adverse effects associated with fluticasone use? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Are there any adverse effects associated with fluticasone use? Three Cochrane Library reviews were found specifically focused on Fluticasone. They each report safety measures as follows: "Review: Fluticasone versus beclomethasone or budesonide for chronic asthma Oropharyngeal

2002 TRIP Answers

10. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Full Text available with Trip Pro

Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in Russian seasonal allergic rhinitis (SAR) patients.Moderate-to-severe SAR/rhinoconjunctivitis patients

2019 International Archives of Allergy and Immunology Controlled trial quality: predicted high

11. Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta) - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) Published 12 February 2018 Product Update fluticasone furoate, umeclidinium, vilanterol (as trifenatate) 92 micrograms / 55 micrograms / 22 micrograms inhalation powder (Trelegy ® Ellipta ® ) SMC No 1303/18 GlaxoSmithKline UK 12 January 2018 The Scottish Medicines Consortium (SMC) has completed its assessment (...) of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy ® Ellipta ® ) is accepted for restricted use within NHS Scotland. Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated

2018 Scottish Medicines Consortium

12. Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma

Arbesda RespiClick - fluticasone propionate / salmeterol xinafoate - Asthma fluticasone propionate / salmeterol xinafoate | CADTH.ca Find the information you need fluticasone propionate / salmeterol xinafoate fluticasone propionate / salmeterol xinafoate Last Updated: March 22, 2019 Result type: Reports Project Number: SR0540-000 Product Line: Generic Name: fluticasone propionate / salmeterol xinafoate Brand Name: Arbesda RespiClick Manufacturer: TEVA Canada Innovation Indications: Asthma (...) request granted - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda December 12, 2018 CDEC Final Recommendation issued to applicant and drug plans December 19, 2018 CDEC Final Recommendation posted December 21, 2018 Final CADTH review report(s) and patient input posted January 17, 2019 Tags asthma, dry powder inhalers, respiratory, respiclick; arbesda; fluticasone propionate; salmeterol; dry powder inhaler; asthmatic; asthmatics Files Follow us: © 2019 Canadian

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

13. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. Full Text available with Trip Pro

Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily fluticasone furoate/vilanterol (FF/VI) versus continuing usual care in asthma patients in UK primary care [ 1 ]. Here, we report a secondary analysis in a subset of patients with fluticasone propionate/salmeterol (FP/Salm) as their baseline intended maintenance therapy

2018 Journal of Asthma Controlled trial quality: predicted high

14. A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (...) (COPD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy

2018 Clinical Trials

15. Comparison of Effectiveness between Beclomethasone Dipropionate and Fluticasone Propionate in Treatment of Children with Moderate Asthma. Full Text available with Trip Pro

Comparison of Effectiveness between Beclomethasone Dipropionate and Fluticasone Propionate in Treatment of Children with Moderate Asthma. Asthma is a common chronic disease. Beclomethasone dipropionate (BDP) and Fluticasone propionate (FP) are 2 inhaled corticosteroids that frequently be used in treatment of patients with asthma. In this study, the effectiveness of BDP and FP in management of asthmatic children was investigated. In this trial, 50 children with moderate persistent asthma were

2013 The World Allergy Organization journal Controlled trial quality: uncertain

16. Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis

Efficacy and safety of fluticasone/salmeterol (Seretide) compared to montelukast (Singulair) in bronchial asthma in under-aged population: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

17. Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved (...) Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical

2017 Clinical Trials

18. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. Full Text available with Trip Pro

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. Long-acting beta-agonists (LABAs) have been shown to increase the risk of asthma-related death among adults and the risk of asthma-related hospitalization among children. It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks. This trial prospectively evaluated the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in children.We (...) randomly assigned, in a 1:1 ratio, children 4 to 11 years of age who required daily asthma medications and had a history of asthma exacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization), as assessed in a time-to-event analysis. The statistical design specified that noninferiority would be shown if the upper boundary

2016 NEJM Controlled trial quality: predicted high

19. Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Aerivio Spiromax (salmeterol xinafoate / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 23 June 2016 EMA/486136/2016 Committee for Medicinal Products (...) for Human Use (CHMP) Assessment report Aerivio Spiromax International non-proprietary name: salmeterol / fluticasone propionate Procedure No. EMEA/H/C/002752/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486136/2016 Page 2/50 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Steps taken for the assessment of the product 7 2. Scientific discussion 8 2.1

2016 European Medicines Agency - EPARs

20. Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive

Airexar Spiromax (salmeterol / fluticasone propionate) - Asthma or Pulmonary Disease, Chronic Obstructive 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 June 2016 EMA/486131/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Airexar Spiromax International non-proprietary name: salmeterol (...) / fluticasone propionate Procedure No. EMEA/H/C/004267/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/486131/2016 Page 2/53 Table of contents 1. Background information on the procedure 6 1.1. Submission of the dossier 6 1.2. Steps taken for the assessment of the product 8 2. Scientific discussion 9 2.1. Introduction 9 2.2. Quality aspects 11 2.2.1. Introduction 11 2.2.2. Active substance 12 Fluticasone propionate

2016 European Medicines Agency - EPARs